Flu universal vaccine
/ GSK
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 12, 2020
A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years
(clinicaltrials.gov)
- P1; N=470; Completed; Sponsor: GlaxoSmithKline; Active, not recruiting ➔ Completed
Clinical • Trial completion • Infectious Disease
1 to 1
Of
1
Go to page
1